December 22, 2025 – Talk Bio

Actionable Insights Powered by AI

AstraZeneca Pays $100M Upfront, Up to $2B Total for Jacobio’s Pan-KRAS Inhibitor JAB-23E73

12 hours ago talkbio0Tagged Antineoplastic Agents, AstraZeneca, Inhibitor, Jacobio Pharma, milestones, pan-KRAS

AstraZeneca; Jacobio Pharma; JAB-23E73; pan-KRAS inhibitor; cancer drug; licensing deal; $100M upfront; $2B milestones

BioMarin Announces $4.8 Billion Acquisition of Amicus Therapeutics for Rare Disease Portfolio Expansion

19 hours ago talkbio0Tagged Acquisition, Amicus Therapeutics, BioMarin, Galafold, Infrequent, Opfolda, Pombiliti +

BioMarin; Amicus Therapeutics; acquisition; $4.8B; Galafold; Pombiliti; Opfolda; rare diseases

FDA Approves Cytokinetics’ Myqorzo for Obstructive Hypertrophic Cardiomyopathy, Positioning It Against BMS’s Camzyos

19 hours ago talkbio0Tagged Aficamten, Approved, Camzyos, Cytokinetics, Hypertrophic obstructive cardiomyopathy, Myers Squibb, Myqorzo, United States Food and Drug Administration

FDA approval; Cytokinetics; Myqorzo; aficamten; obstructive hypertrophic cardiomyopathy; Bristol Myers Squibb; Camzyos

Bayer’s Finerenone Approved in Japan for Chronic Heart Failure Treatment

1 day ago talkbio0Tagged Approved, Bayer, Chronic heart failure, FINEARTS-HF, finerenone, HFmrEF, HFpEF, Japan, Kerendia

Finerenone; Kerendia; Japan approval; chronic heart failure; HFmrEF; HFpEF; Bayer; FINEARTS-HF